Background: Macrophage migration inhibitory factor (MIF) was one of the first lymphokine activities to be discovered and was described almost 30 years ago to be a soluble factor(s) produced by activated T lymphocytes. In more recent studies, MIF has been "rediscovered" to be an abundant, pre-formed constituent of the anterior pituitary gland and the macrophage, and to be a critical component in the host response to septic shock. Pituitary-derived MIF enters the circulation after infectious or stressful stimuli and appears to act to counterregulate glucocorticoid suppression of cytokine production. Materials and Methods: Immunoelectron microscopy utilizing a combination of anti-MIF and anti-pituitary hormone-specific antibodies was used to study the ultrastructural localization of MIF within the anterior pituitary gland. Pituitaries were obtained from resting, unstimulated mice and from mice 16 hr after endotoxin administration. The release of MIF also was investigated in vitro by examining the effect of corticotropin-releasing hormone (CRH) on the AtT-20, corticotrophic cell line.
INTRODUCTION
The protein mediator known as macrophage migration inhibitory factor (MIF) was described originally to be a factor released by activated T lymphocytes which inhibited the random migration of macrophages in vitro (1, 2) . For almost 30 and the administration of neutralizing anti-MIF antibodies fully protects animals from lethal endotoxemia (3) . Within this context, purified recombinant MIF exhibits several important proinflammatory functions. It induces tumor necrosis factor a (TNFa) release from macrophages, acts together with interferon-y (IFN'y) to promote nitric oxide release, and augments the macrophage killing of intracellular pathogens (4, 5) . In distinct contrast to other pro-inflammatory mediators however, the observation has been made that glucocorticoids, at low concentrations, induce rather than inhibit MIF production from monocytes/macrophages and T cells (6) . The MIF which is released from immune cells then acts to "override" the suppressive effect of steroids on cytokine production, indicating that MIF functions physiologically as a counterregulatory mediator to modulate glucocorticoid effects on inflammation and immunity.
The identification of a significant, pituitary source of MIF led us to investigate more closely the ultrastructural location of MIF protein within anterior pituitary cells in vivo. Although mouse MIF first was isolated from the secretory products of a corticotrophic cell line, the sites of MIF production and release from within pituitary gland in vivo have not been precisely established. In the present study, we performed immunoelectron microscopy of mouse pituitary glands that had been stained both with anti-recombinant MIF and with specific anti-ACTH, -TSH, -FSH, -GH, -LH, or -PRL antibodies. MIF was localized to granules contained within ACTH-and TSHsecreting cells and was observed to be released from these cells during endotoxemia. In vitro studies established that CRH is a potent MIF secretogogue, inducing the release of MIF at concentrations lower than that required for ACTH release.
MATERIALS AND METHODS

Animals
Fourteen male BALB/c mice, weighing 25-30 g each, were purchased from Japan SLC Inc. (Hamamatu, Japan). In (7) . Briefly, one side of the grid was treated first with 1% bovine serum albumin in 0.1 M phosphate buffer (PBS-BSA) for 5 min and then with 5 % normal goat serum at room temperature for 5 min. Anti-MIF antiserum was applied to sections at a dilution of 1/300 and incubated for 2 hr. The sections then were washed, treated with 10 nm gold-labeled anti-rabbit IgG for 30 min (Amersham Japan Co., Tokyo, Japan), washed again with 1% PBS-BSA three times, and dried at room temperature. After re-equilibration in 1% PBS-BSA and treatment with normal goat serum for 5 min, the anti-pituitary hormone antisera were applied on the other side of the grid and incubated for 2 hr. The final antibody dilutions were 1/30 for anti-ACTH, anti-TSH, anti-FSH, anti-GH, and anti-LH antisera, and 1/40 for the anti-PRL antiserum. The sections then were washed and treated with 20 nm gold-labeled protein G or anti-rabbit IgG (Amersham Japan). After extensive washing, the sections were counterstained with uranyl acetate. As an additional control for MIF immunoreactivity, positively stained sections were subjected to blocking experiments in which anti-MIF anti-serum first was incubated with purified, mouse MIF (0.01-1 jig/ml) for 1 hr at 37°C. Sections stained with anti-MIF antiserum that had been pre-incubated in this manner were uniformly negative.
For morphological studies, the pituitary gland was fixed in 2.5% glutaraldehyde in 0.1 M PBS. The tissue then was immersed in 1 % osmium tetroxide for post-fixation. The specimens were dehydrated with a graded ethanol series, embedded in Epon 812, and ultrathin sections prepared and stained with uranyl acetate and lead citrate.
Gold-labeled granules were quantified by stereoscopic microscopy of electron micrographs obtained at the magnification of 5,000x. Each scored cell contained 200-300 gold-labeled granules. Statistical analyses were performed using the Mann-Whitney's U test (8) .
In Vitro Studies The mouse corticotrophic cell line AtT-20 was obtained from American Type Culture Collection (Rockville, MD, U.S.A.) and cultured in RPMI/ 1 % fetal bovine serum supplemented with gentamicin (50 ,ug/ml). Synthetic rat CRH was obtained from Calbiochem (La Jolla, CA, U.S.A.) and determined to contain negligible quantities of endotoxin (15 pg of LPS/,ug protein) as assessed by the Limulus amoebocyte assay (BioWhittaker Inc., Walkersville, MD, U.S.A.). For stimulation studies, 1 X 106 cells were cultured in 6-well plates (1 ml total volume) together with CRH (0.01-1000 ng/ml) for 16 hr. The conditioned media then were removed and analyzed for MIF content by a sensitive, MIF-specific sandwich ELISA (C. N. Metz, in preparation) and for ACTH content by radioimmunoassay (ICN, Inc., Costa Mesa, CA, U.S.A.).
RESULTS
In pituitaries obtained from unstimulated, control mice, positive staining for MIF was localized to small secretory granules, which ranged in size from 90 to 200 nm in diameter ( Figs. 1 and 2 (Fig. 6) .
The ACTH-secreting cells comprised two subtypes which followed the morphological classification of Kurosumi et al. (9) . The first type of cells were oval in shape, displayed a few stout processes, and contained secretory granules which filled the entire cytoplasm (Fig. 3) satellite cells with slender processes and secretory granules aligned in a row-like fashion against the outer cell membrane (Fig. 4) Morphologically, the TSH-secreting cells showed a well-developed endoplasmic reticulum and a large number of small secretory granules which ranged in size from 150 to 200 nm in diameter (Fig. 5) . As in the case of the MIFcontaining corticotrophic cells, three types of secretory granules were identified within these cells: those containing MIF alone, those containing TSH alone, and those containing both MIF and TSH.
The release of MIF was investigated by examining MIF localization in pituitary glands that were obtained from seven mice 16 hr after endotoxin injection, a time that corresponds to high circulating MIF levels (3, 4) . A significant decrease in the total number of MIF-containing granules was evident in both the corticotrophic and the thyrotrophic cell types when endotoxintreated mice were compared with control mice (Fig. 7) . The number of MIF-positive granules fell by 38% in corticotrophic cells and by 48% in thyrotrophic cells (p < 0.05). When the granule subtypes were further quantified, the most significant decreases in MIF content occurred only in the granule populations that contained MIF alone (Table 1) . Finally, to begin to obtain insight into the role of hypothalamic releasing factors in the release of MIF from pituitary cells, we studied the effect of CRH on MIF secretion by the mouse AtT-20 corticotrophic cell line. As previously reported (10,1 1), peak ACTH release by these cells was observed at a CRH concentration of approximately 100 ng/ml (Table 2) . CRH also was identified in these experiments to be a potent MIF secretogogue, stimulating MIF release at concentrations that were much lower than that required for peak ACTH secretion.
DISCUSSION
The present study provides the first anatomic and morphological confirmation of recent data indicating that MIF is a prominent, pre-formed constituent of the anterior pituitary gland which is released during circumstances such as endotoxic shock (3) . Significant quantities of MIF are present within the secretory granules contained within the corticotrophic and the thyrotrophic cell populations, which comprise 20 and 5% of the adenohypophyseal cells, respectively. Since the N-terminal sequence of mouse MIF first was obtained from a protein isolated from the secretory products of the line (3) , the localization of immunoreactive MIF to this cell type in vivo is not surprising. The identification of significant quantities of MIF in the granules of thyrotrophic cells was not expected, although in a prior report TSH-containing cells were found to also contain immunoreactive quantities of the cytokine interleukin-1 o3 (12 (6) . At the level of a localized inflammatory site, immune cell MIF acts to balance or counterregulate the anti-inflammatory or immunosuppressive of glucocorticoids.which appear in the circulation as an integral part of the generalized stress response to pain or tissue invasion. The fact that pro-inflammatory stimuli such as endotoxin also lead to the pituitary release of MIF points to the ability of the host to provide a central, counterregulatory response which may serve to balance glucocorticoid effects at the systemic level as well.
